Our Research
In this section
Cardiovascular Disease Research
Revealing new directions for cardiomyopathy research and potential avenues for treatment
Cardiomyopathy is a class of heart disease that affects approximately 1 in 500 people in the UK. Research supported by the Medical and Life Sciences Research Fund could help prevent and/or reverse cardiomyopathy.
Making kidney dialysis safer
This study aims to better understand the causes of hypoxia during haemodialysis by investigating changes in pH, cardiac output, white blood cell count and oxygen status.
Modelling infection susceptibility to Covid19
Recently, the SARS-CoV2 virus has spread rapidly across the globe and has claimed the lives of over 1.1 million people. The virus has led to a state of health emergency in many countries, as well as economic devastation. The scientific community has been working to determine how the virus infects host cells and to identify the contributing genetic factors.
Helping type 2 diabetes patients using therapies to reduce blood glucose
Sodium Glucose Co-Transporter inhibitors have been shown to improve major cardiovascular outcome events including cardiovascular mortality.
Natural phages to inhibit bacterial-associated cardiovascular diseases
It has been shown that heart disease is a condition associated with compounds produced by the gut bacteria, Klebsiella, the main one is a metabolite named trimethylamine, or TMA.
Early cardiac rehabilitation exercise training for patients after cardiac surgery: a randomised controlled trial
Coronary Artery Bypass Graft (CABG) and heart Valve Replacement (VR) operations are common treatments for heart disease and involve cutting through the central chest bone to expose the heart. Pain and loss of strength following this surgery can persist for up to 12 months leaving many patients unable to perform every day activities or return to work. Cardiac rehabilitation exercise (CR) improves recovery and reduces complication
The characterisation of vascular biomarkers and body composition before and after cardiac resynchronisation therapy in patients with chronic heart failure and their role in predicting response.
Heart failure is a common and disabling condition which has a higher death rate than most cancers. The problem continues to expand, despite really effective medical treatments. When patients develop heart failure their heart shape and function alters for the worse.